Reishi Mushroom for Cardiovascular Health

Reishi's cardiovascular pharmacology is a case study in how multiple weak mechanisms can combine into a clinically meaningful pleiotropic effect — while still falling short of the magnitude of effect that justifies replacing established pharmacologic therapy. The triterpenoid fraction contains ganoderic acids that function as in-vitro angiotensin-converting enzyme (ACE) inhibitors, lanostane triterpenoids that weakly inhibit HMG-CoA reductase (the statin target), and ganoderols that modestly enhance endothelial nitric oxide synthase (eNOS) expression. The fruiting body also contains free adenosine, which produces measurable platelet aggregation inhibition. The Klupp 2015 Cochrane review pooled 5 randomized trials of Ganoderma lucidum for cardiovascular risk factors in type 2 diabetes (a total of 398 patients) and concluded that the effects on lipid profile, blood pressure, and glycemic control were modest and statistically uncertain. This article walks through each individual cardiovascular mechanism, the meta-analytic evidence base, the clinical contexts where Reishi is appropriate as adjunct, and the contexts where it is not.

Table of Contents

  1. A Multi-Target Cardiovascular Profile
  2. ACE Inhibition by Ganoderic Acids
  3. HMG-CoA Reductase Inhibition (the Weak-Statin Mechanism)
  4. eNOS Activation and Endothelial Function
  5. Antiplatelet Effect via Adenosine
  6. Lipid Profile: HDL, LDL, Triglycerides
  7. Glycemic Control and Type 2 Diabetes
  8. The Klupp 2015 Cochrane Review
  9. Clinical Applications — When to Use, When Not
  10. Cautions and Drug Interactions
  11. Key Research Papers
  12. Connections

A Multi-Target Cardiovascular Profile

Pharmaceutical cardiovascular drugs are typically single-target: a statin inhibits HMG-CoA reductase, an ACE inhibitor blocks angiotensin-converting enzyme, aspirin acetylates platelet cyclooxygenase. Each does one thing strongly. Reishi, in contrast, does many things weakly: a mild ACE inhibition, a mild HMG-CoA reductase inhibition, a mild eNOS enhancement, a mild antiplatelet effect, and a mild insulin-sensitizing effect.

The pharmacologic question is whether the combination of many weak effects produces a clinically meaningful net result. The answer in the cardiovascular space appears to be "yes in some populations, modestly, but not enough to substitute for proven pharmaceutical therapy in established cardiovascular disease." Reishi's appropriate role is therefore as an adjunct in primary prevention populations with moderate risk who are already implementing diet and exercise interventions and may benefit from additional mild pleiotropic support — not as a treatment for established hypertension, hyperlipidemia, or coronary artery disease.

This is an important framing because Reishi has at times been marketed in the supplement industry with implicit claims that overstate its cardiovascular effects. A realistic understanding of the evidence base is critical to setting appropriate patient expectations.

Back to Table of Contents

ACE Inhibition by Ganoderic Acids

The renin-angiotensin-aldosterone system (RAAS) is the principal pharmacologic target for the management of hypertension and heart failure. Angiotensin-converting enzyme (ACE) cleaves the inactive decapeptide angiotensin I into the active octapeptide angiotensin II, which acts on AT1 receptors to produce vasoconstriction, aldosterone release, and increased sympathetic tone. Pharmacologic ACE inhibitors (lisinopril, ramipril, enalapril) block this conversion and produce a robust 10–20 mmHg reduction in systolic blood pressure in hypertensive patients.

Multiple Ganoderma lucidum triterpenoids have been shown in vitro to inhibit ACE activity. The most potent appear to be ganoderic acids B and F, with IC50 values in the low micromolar range. The in-vivo significance of these in-vitro findings is unclear because the systemic concentrations of ganoderic acids achieved after oral Reishi administration are typically below the micromolar range — the in-vitro IC50 may not be reached at the relevant tissue site.

Human blood pressure trials of Reishi have shown small, statistically significant reductions in systolic and diastolic pressure (typically 5–10 mmHg in hypertensive subjects, less in normotensive subjects). The effect size is roughly 30–50% of what would be expected from a low-dose pharmaceutical ACE inhibitor. Reishi is therefore reasonable as adjunct in mild stage-1 hypertension where the patient is reluctant to start prescription therapy, but should not substitute for pharmaceutical ACE inhibition in stage-2 hypertension, established heart failure, or proteinuric chronic kidney disease where the evidence-based effect of pharmacologic RAAS blockade is robust.

Back to Table of Contents

HMG-CoA Reductase Inhibition (the Weak-Statin Mechanism)

HMG-CoA reductase is the rate-limiting enzyme of cholesterol biosynthesis, converting 3-hydroxy-3-methylglutaryl-CoA to mevalonate. Statins (atorvastatin, rosuvastatin, simvastatin) bind the active site competitively and reduce hepatic cholesterol synthesis, which in turn upregulates LDL receptor expression and accelerates clearance of circulating LDL particles.

Several Reishi lanostane triterpenoids share structural features with the statin pharmacophore and can be shown in vitro to inhibit HMG-CoA reductase, though with potency that is approximately 100–1,000-fold lower than pharmaceutical statins. The clinical translation is a modest LDL-lowering effect — typically 5–15% reduction in fasting LDL with sustained Reishi use, compared to 30–55% reduction achievable with moderate-to-high-intensity statin therapy.

The Klupp 2015 Cochrane review found a numerically positive but statistically nonsignificant trend toward LDL reduction with Reishi in diabetic patients. Other trial populations have shown more consistent LDL reduction. The mechanism makes Reishi a reasonable adjunct for patients with borderline hyperlipidemia who do not yet meet criteria for statin therapy, or for statin-intolerant patients seeking modest pleiotropic support, but not a substitute for statin therapy in patients with established atherosclerotic cardiovascular disease or familial hypercholesterolemia.

For more on cholesterol management, see our Hyperlipidemia page.

Back to Table of Contents

eNOS Activation and Endothelial Function

Endothelial nitric oxide synthase (eNOS) produces nitric oxide (NO) from L-arginine in the vascular endothelium. NO diffuses to underlying vascular smooth muscle and produces relaxation, contributing to the moment-to-moment regulation of vascular tone. Endothelial dysfunction — reduced eNOS activity and NO bioavailability — is the earliest measurable abnormality in the progression toward atherosclerotic cardiovascular disease, preceding hypertension, lipid abnormalities, and overt plaque formation.

Reishi extracts and isolated triterpenoid fractions have been shown to upregulate eNOS expression in cultured human umbilical vein endothelial cells (HUVECs) and to improve flow-mediated dilation in animal models of endothelial dysfunction. The proposed mechanism involves modulation of the PI3K/Akt pathway, which phosphorylates eNOS at Ser1177 and increases enzymatic activity.

Whether this in-vitro and animal-model finding translates to clinically meaningful improvement in endothelial function in human cardiovascular disease patients remains uncertain. The translation to hard cardiovascular endpoints (myocardial infarction, stroke, cardiovascular mortality) requires much larger and longer trials than have been performed for Reishi. The mechanism is plausible and the direction of effect is favorable, but the evidence base does not yet support specific clinical recommendations.

Back to Table of Contents

Antiplatelet Effect via Adenosine

Reishi fruiting bodies contain pharmacologically meaningful quantities of free adenosine. Adenosine binds A2A and A2B receptors on platelet surfaces, activates adenylyl cyclase, increases intracellular cyclic AMP, and inhibits platelet aggregation in response to thrombin, collagen, and ADP. This is the same general mechanism (though not the same target receptor) that dipyridamole exploits as an antiplatelet drug.

The Reishi antiplatelet effect is measurable in vitro using platelet aggregation assays and is reproducible in animal models. The magnitude is modest — nothing like the dramatic effect of aspirin, clopidogrel, or modern P2Y12 inhibitors — but is clinically relevant in two specific contexts:

  1. Bleeding risk on anticoagulant therapy — patients on warfarin or direct oral anticoagulants who also take Reishi may have additive bleeding risk and should monitor for bruising, gum bleeding, or any unexplained anemia
  2. Preoperative discontinuation — Reishi should be discontinued at least 2 weeks before any planned surgery to avoid additive antiplatelet effect, similar to standard recommendations for fish oil, ginkgo, and garlic supplements

The mild antiplatelet effect is generally considered favorable for cardiovascular health (reducing thrombotic risk), but the bleeding-risk caveats apply across all populations.

Back to Table of Contents

Lipid Profile: HDL, LDL, Triglycerides

Pooled data on Reishi's effect on the complete lipid profile shows:

The pattern is consistent with a mild pleiotropic effect across the lipid profile rather than a strong effect on any one lipid fraction. For a patient with isolated borderline hyperlipidemia and moderate cardiovascular risk score, Reishi may be a reasonable adjunct to diet and exercise interventions. For a patient with established atherosclerotic cardiovascular disease, the effect size is too modest to substitute for evidence-based statin therapy.

Patients should be evaluated with a standard lipid panel at baseline and again 12 weeks after starting Reishi to assess individual response.

Back to Table of Contents

Glycemic Control and Type 2 Diabetes

Reishi polysaccharides have shown insulin-sensitizing and modest glucose-lowering effects in multiple animal models of type 2 diabetes, with proposed mechanisms including improved insulin receptor signaling, reduced hepatic gluconeogenesis, and improved peripheral glucose uptake. The Klupp 2015 Cochrane review focused specifically on Reishi in type 2 diabetes and found:

For diabetic patients already on metformin or insulin, Reishi's potential additive hypoglycemic effect warrants more careful glucose monitoring during initiation. For non-diabetic patients with metabolic syndrome or prediabetes, Reishi's modest glycemic effects are unlikely to substitute for lifestyle intervention but may complement it as an additional supportive measure.

Back to Table of Contents

The Klupp 2015 Cochrane Review

The Klupp et al. 2015 Cochrane Database systematic review titled "Ganoderma lucidum mushroom for the treatment of cardiovascular risk factors" remains the highest-quality synthesis of the cardiovascular evidence base for Reishi. The review pooled 5 randomized controlled trials enrolling a total of 398 type-2-diabetic patients, with intervention durations ranging from 4 to 24 weeks.

Outcomes assessed:

Conclusions:

The included studies were small, low to moderate quality, and there was insufficient evidence to support or refute the use of Ganoderma lucidum for the treatment of cardiovascular risk factors in people with type 2 diabetes. Further well-designed, adequately powered, randomized controlled trials are needed.

This Cochrane conclusion remains the benchmark and has not been substantially updated by subsequent meta-analyses. The honest summary is that Reishi may have favorable cardiovascular effects but the evidence base is not yet robust enough to make specific clinical recommendations beyond cautious adjunct use in selected populations.

Back to Table of Contents

Clinical Applications — When to Use, When Not

Based on the evidence base summarized above, reasonable clinical applications for Reishi in the cardiovascular space include:

Inappropriate uses include:

Back to Table of Contents

Cautions and Drug Interactions

Back to Table of Contents

Key Research Papers

  1. Klupp NL et al. (2015). Ganoderma lucidum mushroom for the treatment of cardiovascular risk factors. Cochrane Database of Systematic Reviews. — PubMed
  2. Morigiwa A et al. (1986). Angiotensin-converting enzyme inhibitory triterpenes from Ganoderma lucidum. Chemical and Pharmaceutical Bulletin. — PubMed
  3. Komoda Y et al. (1989). Ganoderic acid derivatives and HMG-CoA reductase inhibition. Chemical and Pharmaceutical Bulletin. — PubMed
  4. Tao J, Feng KY (1990). Experimental and clinical studies on inhibitory effect of Ganoderma lucidum on platelet aggregation. Journal of Tongji Medical University. — PubMed
  5. Chu TT et al. (2012). Study of potential cardioprotective effects of Ganoderma lucidum (Lingzhi): results of a controlled human intervention trial. British Journal of Nutrition. — PubMed
  6. Wachtel-Galor S et al. (2004). The effect of Ganoderma lucidum supplementation on antioxidant status in healthy human subjects. British Journal of Nutrition. — PubMed
  7. Mohammed A et al. (2007). Inhibitory effect of triterpenes from Ganoderma lucidum on the binding of [125I]angiotensin II to AT1 receptor. Phytotherapy Research. — PubMed
  8. Wihastuti TA et al. (2015). Anti-atherosclerotic effect of Ganoderma lucidum polysaccharide peptide. Vascular Health and Risk Management. — PubMed
  9. Berger A et al. (2004). Cholesterol-lowering properties of Ganoderma lucidum in vitro, ex vivo, and in hamsters and minipigs. Lipids in Health and Disease. — PubMed
  10. Gao Y et al. (2004). A phase I/II study of a Ganoderma lucidum extract in patients with chronic hepatitis B. International Journal of Medicinal Mushrooms. — PubMed
  11. Hsu CL et al. (2008). Hypolipidemic effect of Ganoderma lucidum polysaccharides in oxidative stress-induced renal injury. Food and Chemical Toxicology. — PubMed
  12. Pan D et al. (2013). Antihypertensive and antioxidant effects of Ganoderma lucidum polysaccharide in spontaneously hypertensive rats. International Journal of Biological Macromolecules. — PubMed

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents